CA2547873C - Tetrapetpide regulant le taux de sucre sanguin dans le cadre du diabete sucre - Google Patents
Tetrapetpide regulant le taux de sucre sanguin dans le cadre du diabete sucre Download PDFInfo
- Publication number
- CA2547873C CA2547873C CA2547873A CA2547873A CA2547873C CA 2547873 C CA2547873 C CA 2547873C CA 2547873 A CA2547873 A CA 2547873A CA 2547873 A CA2547873 A CA 2547873A CA 2547873 C CA2547873 C CA 2547873C
- Authority
- CA
- Canada
- Prior art keywords
- glu
- asp
- tetrapeptide
- trp
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La présente invention fait référence au domaine de la médecine et peut s'appliquer en tant que substance capable de réguler le taux de glucose tout en traitant et en évitant le diabète sucré. L'invention concerne un nouveau tétrapeptide lysyl-glutamyl-aspartyl-tryptophane à action biologique de formule générale Lys-Glu-Asp-Trp-NH¿2? capable de réguler le taux de glucose, et une substance pharmaceutiquement acceptable contenant une quantité efficace de tétrapeptide lysyl-glutamyl-aspartyl-tryptophane de formule générale Lys-Glu-Asp-Trp-NH¿2?. L'invention a également pour objet un procédé pour prévenir et/ou traiter le diabète sucré, qui consiste à administrer à un patient une substance pharmacologique contenant comme principe actif peptidique une quantité efficace de tétrapeptide Lys-Glu-Asp-Trp-NH¿2? selon des doses de 0,1 - 30 ?g/kg de masse corporelle, au moins une fois par jour pendant un durée nécessaire pour obtenir l'effet thérapeutique souhaité.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2003135605 | 2003-12-10 | ||
RU2003135605/15A RU2242241C1 (ru) | 2003-12-10 | 2003-12-10 | Тетрапептид, регулирующий уровень глюкозы при сахарном диабете, фармакологическое средство на его основе и способ его применения |
PCT/RU2004/000318 WO2005056580A1 (fr) | 2003-12-10 | 2004-08-09 | Tetrapetpide regulant le taux de sucre sanguin dans le cadre du diabete sucre |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2547873A1 CA2547873A1 (fr) | 2005-06-23 |
CA2547873C true CA2547873C (fr) | 2011-11-22 |
Family
ID=34388701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2547873A Expired - Fee Related CA2547873C (fr) | 2003-12-10 | 2004-08-09 | Tetrapetpide regulant le taux de sucre sanguin dans le cadre du diabete sucre |
Country Status (15)
Country | Link |
---|---|
US (1) | US7491703B2 (fr) |
EP (1) | EP1697401B1 (fr) |
JP (1) | JP2007537140A (fr) |
KR (1) | KR101106609B1 (fr) |
AT (1) | ATE454397T1 (fr) |
AU (1) | AU2004296269B2 (fr) |
CA (1) | CA2547873C (fr) |
DE (1) | DE602004025040D1 (fr) |
DK (1) | DK1697401T3 (fr) |
EA (1) | EA008541B1 (fr) |
LT (1) | LT5421B (fr) |
LV (1) | LV13462B (fr) |
RU (1) | RU2242241C1 (fr) |
UA (1) | UA85204C2 (fr) |
WO (1) | WO2005056580A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2295970C1 (ru) | 2006-05-23 | 2007-03-27 | Общество С Ограниченной Ответственностью "Сиа Пептайдс" | Пептид, повышающий резистентность капилляров, фармацевтическая композиция на его основе и способ ее применения |
RU2304444C1 (ru) | 2006-05-23 | 2007-08-20 | Общество С Ограниченной Ответственностью "Сиа Пептайдс" | Пептид, обладающий стресспротекторным действием, фармацевтическая композиция на его основе и способ ее применения |
RU2301074C1 (ru) | 2006-05-30 | 2007-06-20 | Общество С Ограниченной Ответственностью "Сиа Пептайдс" | Пептид, обладающий иммуногеропротекторным действием, фармацевтическая композиция на его основе и способ ее применения |
RU2301678C1 (ru) | 2006-05-30 | 2007-06-27 | Общество С Ограниченной Ответственностью "Сиа Пептайдс" | Пептид, стимулирующий регенерацию нейронов центральной нервной системы, фармацевтическая композиция на его основе и способ ее применения |
RU2613314C2 (ru) * | 2013-06-28 | 2017-03-15 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Малые молекулы с NGF-подобной активностью, обладающие антидиабетическими свойствами |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3411284A1 (de) * | 1984-03-27 | 1985-10-10 | Wacker-Chemie GmbH, 8000 München | Organo(poly)siloxane und derartige organo(poly)siloxane enthaltende, durch bestrahlung mit licht vernetzbare massen |
US6180103B1 (en) | 1994-12-21 | 2001-01-30 | Yeda Research And Development Co., Ltd. | Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes |
IL112094A0 (en) | 1994-12-21 | 1995-03-15 | Yeda Res & Dev | Novel peptides and pharmaceutical compositions comprising them |
RU2078769C1 (ru) | 1995-08-18 | 1997-05-10 | Научно-исследовательский институт биомедицинской химии РАМН | Пептидный фрагмент, обладающий биологической активностью инсулина |
AUPQ661800A0 (en) * | 2000-03-31 | 2000-05-04 | Metabolic Pharmaceuticals Limited | Insulin-potentiating compounds |
RU2166957C1 (ru) * | 2000-10-09 | 2001-05-20 | Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" | Тетрапептид, стимулирующий функциональную активность гепатоцитов, фармакологическое средство на его основе и способ его применения |
EP1499350A4 (fr) * | 2001-08-31 | 2006-02-08 | Agensys Inc | Acide nucleique et proteine correspondante appelee 205p1b5 utilises dans le traitement et la detection du cancer |
-
2003
- 2003-12-10 RU RU2003135605/15A patent/RU2242241C1/ru not_active IP Right Cessation
-
2004
- 2004-08-09 KR KR1020067011267A patent/KR101106609B1/ko active IP Right Grant
- 2004-08-09 EP EP04775257A patent/EP1697401B1/fr not_active Not-in-force
- 2004-08-09 DE DE602004025040T patent/DE602004025040D1/de active Active
- 2004-08-09 CA CA2547873A patent/CA2547873C/fr not_active Expired - Fee Related
- 2004-08-09 AT AT04775257T patent/ATE454397T1/de active
- 2004-08-09 JP JP2006543758A patent/JP2007537140A/ja active Pending
- 2004-08-09 DK DK04775257.1T patent/DK1697401T3/da active
- 2004-08-09 US US10/580,957 patent/US7491703B2/en not_active Expired - Fee Related
- 2004-08-09 AU AU2004296269A patent/AU2004296269B2/en not_active Ceased
- 2004-08-09 WO PCT/RU2004/000318 patent/WO2005056580A1/fr active IP Right Grant
- 2004-08-09 EA EA200600757A patent/EA008541B1/ru not_active IP Right Cessation
- 2004-09-08 UA UAA200606558A patent/UA85204C2/uk unknown
-
2006
- 2006-04-05 LT LT2006024A patent/LT5421B/lt not_active IP Right Cessation
- 2006-04-06 LV LVP-06-55A patent/LV13462B/en unknown
Also Published As
Publication number | Publication date |
---|---|
UA85204C2 (uk) | 2009-01-12 |
LT2006024A (en) | 2007-02-26 |
LT5421B (lt) | 2007-05-25 |
EP1697401A1 (fr) | 2006-09-06 |
US7491703B2 (en) | 2009-02-17 |
RU2242241C1 (ru) | 2004-12-20 |
LV13462B (en) | 2007-02-20 |
JP2007537140A (ja) | 2007-12-20 |
WO2005056580A1 (fr) | 2005-06-23 |
DE602004025040D1 (de) | 2010-02-25 |
AU2004296269B2 (en) | 2010-06-03 |
US20070142298A1 (en) | 2007-06-21 |
AU2004296269A1 (en) | 2005-06-23 |
EA008541B1 (ru) | 2007-06-29 |
KR20070022199A (ko) | 2007-02-26 |
EA200600757A1 (ru) | 2006-08-25 |
EP1697401B1 (fr) | 2010-01-06 |
DK1697401T3 (da) | 2010-05-03 |
CA2547873A1 (fr) | 2005-06-23 |
KR101106609B1 (ko) | 2012-01-20 |
ATE454397T1 (de) | 2010-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0489860B1 (fr) | Procedes et compositions pour la guerison d'ulceres | |
USRE43309E1 (en) | Immunoregulatory compositions | |
JP3957751B2 (ja) | 新規ドラスタチン誘導体、その製法及び使用 | |
AU784578B2 (en) | Tetrapeptide stimulating functional activity of neurones, pharmacological agent based thereon and method of use thereof | |
JPH02500275A (ja) | 潰瘍の予防のための方法及び組成物 | |
JPH0150684B2 (fr) | ||
HU221092B1 (en) | Compounds with growth hormone releasing properties | |
KR880002608B1 (ko) | 펩타이드 유도체의 제법 | |
LV13462B (en) | Tetrapeptide regulating blood glucose level in diabetes mellitus | |
KR101865420B1 (ko) | 벡터적 이온 채널의 조절을 위한 유기화합물 | |
RU2362579C1 (ru) | Фармацевтическая композиция на основе пептида, обладающего противоопухолевым действием | |
CN101302246B (zh) | 黑色素皮质激素受体七肽类激动剂及其制备方法和用途 | |
US4390528A (en) | Tuftsinyl-tuftsin | |
CA2300373A1 (fr) | Modulateur immunologique ayant une activite antimicrobienne et anti-mycobacterienne, procede de production de ce modulateur et preparation pharmaceutique permettant de traiter les mycobacterioses ainsi que les affections chroniques et non specifiques des poumons, les maladies sexuellement transmissibles et le deficit immuni | |
EP1353939B1 (fr) | Tetrapeptide regulant les fonctions de la prostate, substance pharmacologique a base de ce tetrapeptide et ses applications | |
DE3034531C2 (de) | Verwendung von Polypeptiden als Analgetikum in der Human- und Tiermedizin | |
JP2868800B2 (ja) | 癌転移抑制剤 | |
WO2002030955A2 (fr) | Substance tetrapeptidique stimulant l'activite fonctionnelle des hepatocytes, substance pharmacologique obtenue sur cette base et procede d'application | |
JP2022177648A (ja) | 血糖降下組成物、及びそれを含有する血糖降下薬剤 | |
AU2014203176B2 (en) | Transdermal delivery systems of peptides and related compounds | |
KR20220102128A (ko) | 신규 그렐린 유사체 및 이를 함유하는 아밀로이드 베타 응집 관련 질환의 예방 또는 치료용 약학 조성물 | |
JPH03120295A (ja) | 抗健忘症作用を有する新規なcns―活性ヘキサペプチド | |
JPH07506564A (ja) | 医薬的ペンタペプチド組成物およびその使用法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20220301 |
|
MKLA | Lapsed |
Effective date: 20200831 |